Asthma remains a significant health burden in the U.S., with more than 60% of adults continuing to experience frequent symptoms despite the ...

Switching asthma patients from a pressurised metered dose inhaler (pMDI) to a dry powder inhaler (DPI) for maintenance therapy more than halves their carbon footprint without loss of asthma control, ...

Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered ...

AstraZeneca Announces Symbicort Is Now Available In The U.S. U.S. Asthma Sufferers Now Have a New Choice of Combination Therapy to Help Achieve Asthma Control LONDON ...

If you're having an asthma attack, you assume that with each puff of your inhaler you are getting relief. But, in many cases, it seems inhalers are being used long after they have run out of ...

hands holding a smart phone How effective are add-on devices for pressurized metered-dose inhalers in helping patients with asthma to avoid poor outcomes associated with incorrect inhaler use? In ...

The purpose of selecting an appropriate inhaler device is to improve patient adherence and inhaler technique to achieve the goals of therapy for patients with COPD. In 2005, the American College of ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients who ...

LONDON, UK, 7 March 2011 - SkyePharma PLC (LSE: SKP) today announces that AstraZeneca has informed it of a decision to discontinue production of PULMICORT (budesonide) 100 and 200 µg/dose HFA pMDI ...